166 related articles for article (PubMed ID: 34365557)
1. Circulating Hybrid Cells: A Novel Liquid Biomarker of Treatment Response in Gastrointestinal Cancers.
Walker BS; Sutton TL; Zarour L; Hunter JG; Wood SG; Tsikitis VL; Herzig DO; Lopez CD; Chen EY; Mayo SC; Wong MH
Ann Surg Oncol; 2021 Dec; 28(13):8567-8578. PubMed ID: 34365557
[TBL] [Abstract][Full Text] [Related]
2. Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma.
Cabalag CS; Yates M; Corrales MB; Yeh P; Wong SQ; Zhang BZ; Fujihara KM; Chong L; Hii MW; Dawson SJ; Phillips WA; Duong CP; Clemons NJ
Ann Surg; 2022 Aug; 276(2):e120-e126. PubMed ID: 35737908
[TBL] [Abstract][Full Text] [Related]
3. Signet Ring Cell Features are Associated with Poor Response to Neoadjuvant Treatment and Dismal Survival in Patients with High-Grade Esophageal Adenocarcinoma.
Solomon D; Abbas M; Feferman Y; Haddad R; Perl G; Kundel Y; Morgenstern S; Menasherov N; Kashtan H
Ann Surg Oncol; 2021 Sep; 28(9):4929-4940. PubMed ID: 33709175
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy.
Agoston AT; Zheng Y; Bueno R; Lauwers GY; Odze RD; Srivastava A
Am J Surg Pathol; 2015 Aug; 39(8):1085-92. PubMed ID: 26076061
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant treatment response in negative nodes is an important prognosticator after esophagectomy.
Nieman DR; Peyre CG; Watson TJ; Cao W; Lunt MD; Lada MJ; Han MS; Jones CE; Peters JH
Ann Thorac Surg; 2015 Jan; 99(1):277-83. PubMed ID: 25442991
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of miR-21 and miR-375 as prognostic biomarkers in esophageal cancer.
Winther M; Alsner J; Tramm T; Baeksgaard L; Holtved E; Nordsmark M
Acta Oncol; 2015; 54(9):1582-91. PubMed ID: 26481465
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinoma.
Yakirevich E; Lu S; Allen D; Mangray S; Fanion JR; Lombardo KA; Safran H; Resnick MB
Hum Pathol; 2017 Aug; 66():126-135. PubMed ID: 28666927
[TBL] [Abstract][Full Text] [Related]
8. P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy.
van Olphen SH; Biermann K; Shapiro J; Wijnhoven BP; Toxopeus EL; van der Gaast A; Stoop HA; van Lanschot JJ; Spaander MC; Bruno MJ; Looijenga LH
Ann Surg; 2017 Feb; 265(2):347-355. PubMed ID: 28059963
[TBL] [Abstract][Full Text] [Related]
9. Specific gene expression profiles are associated with a pathologic complete response to neoadjuvant therapy in esophageal adenocarcinoma.
McLaren PJ; Barnes AP; Terrell WZ; Vaccaro GM; Wiedrick J; Hunter JG; Dolan JP
Am J Surg; 2017 May; 213(5):915-920. PubMed ID: 28385379
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus.
Shah AK; Hartel G; Brown I; Winterford C; Na R; Cao KL; Spicer BA; Dunstone MA; Phillips WA; Lord RV; Barbour AP; Watson DI; Joshi V; Whiteman DC; Hill MM
Mol Cell Proteomics; 2018 Dec; 17(12):2324-2334. PubMed ID: 30097534
[TBL] [Abstract][Full Text] [Related]
11. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma.
Xi M; Hallemeier CL; Merrell KW; Liao Z; Murphy MAB; Ho L; Hofstetter WL; Mehran R; Lee JH; Bhutani MS; Weston B; Maru DM; Komaki R; Ajani JA; Lin SH
Ann Surg; 2018 Aug; 268(2):289-295. PubMed ID: 28628563
[TBL] [Abstract][Full Text] [Related]
12. Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.
Schwameis K; Zehetner J; Hagen JA; Oh DS; Worrell SG; Rona K; Cheng N; Samaan J; Green KM; Lipham JC
Surg Oncol; 2017 Dec; 26(4):522-526. PubMed ID: 29113673
[TBL] [Abstract][Full Text] [Related]
13. Association of Matrix Metalloproteinase 7 Expression With Pathologic Response After Neoadjuvant Treatment in Patients With Resected Pancreatic Ductal Adenocarcinoma.
Shoucair S; Chen J; Martinson JR; Habib JR; Kinny-Köster B; Pu N; van Oosten AF; Javed AA; Shin EJ; Ali SZ; Lafaro KJ; Wolfgang CL; He J; Yu J
JAMA Surg; 2022 Jul; 157(7):e221362. PubMed ID: 35612832
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma.
Groth SS; Burt BM; Farjah F; Smaglo BG; Sada YH; Sugarbaker DJ; Massarweh NN
J Thorac Cardiovasc Surg; 2019 Apr; 157(4):1682-1693.e1. PubMed ID: 30711279
[TBL] [Abstract][Full Text] [Related]
15. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma.
Malaisrie SC; Hofstetter WL; Correa AM; Ajani JA; Komaki RR; Rice DC; Vaporciyan AA; Walsh GL; Roth JA; Wu TT; Swisher SG
Cancer; 2006 Sep; 107(5):967-74. PubMed ID: 16874819
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic determinants of pathologic treatment response in neoadjuvant treated rectal adenocarcinoma.
González I; Bauer PS; Chapman WC; Alipour Z; Rais R; Liu J; Chatterjee D
Ann Diagn Pathol; 2020 Apr; 45():151452. PubMed ID: 31945621
[TBL] [Abstract][Full Text] [Related]
17. Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer.
Hammoud ZT; Kesler KA; Ferguson MK; Battafarrano RJ; Bhogaraju A; Hanna N; Govindan R; Mauer AA; Yu M; Einhorn LH
Dis Esophagus; 2006; 19(2):69-72. PubMed ID: 16643172
[TBL] [Abstract][Full Text] [Related]
18. Association of Intervals Between Neoadjuvant Chemoradiation and Surgical Resection With Pathologic Complete Response and Survival in Patients With Esophageal Cancer.
Haisley KR; Laird AE; Nabavizadeh N; Gatter KM; Holland JM; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
JAMA Surg; 2016 Nov; 151(11):e162743. PubMed ID: 27627765
[TBL] [Abstract][Full Text] [Related]
19. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Abdelrahman AM; Goenka AH; Alva-Ruiz R; Yonkus JA; Leiting JL; Graham RP; Merrell KW; Thiels CA; Hallemeier CL; Warner SG; Haddock MG; Grotz TE; Tran NH; Smoot RL; Ma WW; Cleary SP; McWilliams RR; Nagorney DM; Halfdanarson TR; Kendrick ML; Truty MJ
J Natl Compr Canc Netw; 2022 Sep; 20(9):1023-1032.e3. PubMed ID: 36075389
[TBL] [Abstract][Full Text] [Related]
20. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
